Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas

Journal of Virology

Volumn 78, Issue 4, 2004, Pages 1893-1902

  Feng, Wen Hai ^a   Hong, Gregory ^a   Delecluse, Henri Jacques ^b   Kenney, Shannon C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; THYMIDINE KINASE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING SITE; BRLF1 GENE; BZLF1 GENE; CELL KILLING; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE DELETION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; LYMPHOBLASTOID CELL; LYMPHOCYTE TRANSFORMATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS GENE; VIRUS INDUCTION; VIRUS INFECTION; VIRUS LATENCY; VIRUS MUTANT; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; DEOXYCYTIDINE; DOXORUBICIN; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VIRUS ACTIVATION;

EID: 0842326026     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.4.1893-1902.2004     Document Type: Article

References (58)

1. Abdu, B., S. Sabri, D. Zelenika, E. Deutsch, V. Frascogna, J. Klijanienko, W. Vainchenker, I. Joab, and J. Bourhis. 2003. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 22:2260-2271.
2. Adamson, A. L., D. Darr, E. Holley-Guthrie, R. A. Johnson, A. Mauser, J. Swenson, and S. Kenney. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74:1224-1233.
3. Adamson, A. L., and S. C. Kenney. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z (S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
4. Ambinder, R., K. Robertson, S. Moore, and J. Yang. 1996. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin. Cancer Biol. 7:217-227.
5. Arai, M., A. Yoguchi, T. Takizawa, T. Yokoyama, T. Kanda, M. Kurabayashi, and R. Nagai. 2000. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ. Res. 86:8-14.
6. Ben-Sasson, S. A., and G. Klein. 1981. Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int. J. Cancer 28:131-135.
7. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou, G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl. Cancer Inst. 91:1376-1381.
8. Borras, A. M., J. L. Strominger, and S. H. Speck. 1996. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J. Virol. 70:3894-3901.
9. Bryant, H., and P. J. Farrell. 2002. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J. Virol. 76:10290-10298.
10. Cazaux, C., M. Tiraby, L. Loubiere, L. Haren, D. Klatzmann, and G. Tiraby. 1998. Phosphorylation and cytotoxicity of therapeutic nucleoside analogues: a comparison of alpha and gamma herpesvirus thymidine kinase suicide genes. Cancer Gene Ther. 5:83-91.
11. Chen, M. R., S. J. Chang, H. Huang, and J. Y. Chen. 2000. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J. Virol. 74:3093-3104.
12. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J. 5:3243-3249.
13. Cohen, J. I. 2000. Epstein-Barr virus infection. N. Engl. J. Med. 343:481-492.
14. Conners, T. A. 1995. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2:702-709.
15. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-4089.
16. Darr, C. D., A. Mauser, and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75:6135-6142.
17. Faggioni, A., C. Zompetta, S. Grimaldi, G. Barile, L. Frati, and J. Lazdins. 1986. Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 232:1554-1556.
18. Fahmi, H., C. Cochet, Z. Hmama, P. Opolon, and I. Joab. 2000. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J. Virol. 74:5810-5818.
19. Feederle, R., M. Kost, M. Baumann, A. Janz, E. Drouet, W. Hammerschmidt, and H. J. Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
20. Feng, W.-H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic Epstein-Barr virus (EBV) replication and confers ganciclovir susceptibility to EBV-positive tumors. Cancer Res. 62:1920-1926.
21. Feng, W.-H., E. Westphal, A. Mauser, N. Raab-Traub, M. L. Gulley, P. Busson, and S. C. Kenney. 2002. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J. Virol. 76:10951-10959.
22. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226.
23. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. L. Moolten, and G. N. Abraham. 1993. The "bystander" effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274-5283.
24. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
25. Grinstein, S., M. V. Preciado, P. Gattuso, P. A. Chabay, W. H. Warren, E. D. Matteo, and V. E. Gould. 2002. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res. 62:4876-4878.
26. Gruffat, H., E. Manet, and A. Sergeant. 2000. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3:141-146.
27. Guitierrez, M. I., J. G. Judde, I. Magrath, and K. G. Bhatia. 1996. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res. 56:969-972.
28. Gustafson, E. A., A. C. Chillemi, D. R. Sage, and J. D. Fingeroth. 1998. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob. Agents Chemother. 42:2923-2931.
29. Israel, B. I., R. J. Pickles, D. M. Segal, R. D. Gerard, and S. C. Kenney. 2001. Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody. J. Virol. 75:5215-5221.
30. Kenney, S., J.-Q. Ge, E. M. Westphal, and J. Olsen. 1998. Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum. Gene Ther. 9:1131-1141.
31. Kieff, E. 2001. Epstein-Barr virus and its replication, p. 2511-2573. In B. Fields, D. Knipe, and P. Howley (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, Pa.
32. Lim, C. P., N. Jain, and X. Cao. 1998. Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 16:2915-2926.
33. Lin, J. C., D. Nelson, C. Lambe, and E. Cho. 1986. Metabolic activation of 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr Virus. J. Virol. 60:569-573.
34. Lin, J. C., C. Smith, and J. Pagano. 1984. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50:50-55.
35. Liu, S., P. Liu, A. Borras, T. Chatila, and S. H. Speck. 1997. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 16:143-153.
36. Livingstone, C., G. Patel, and N. Jones. 1995. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J. 14:1785-1797.
37. Loublere, L., M. Tiraby, C. Cazaux, E. Brisson, M. Grisoni, J. Zhao-Emonet, G. Tiraby, and D. Klatzmann. 1999. The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase. Gene Ther. 6:1638-1642.
38. Luka, J., B. Kallin, and G. Klein. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231.
39. Mentzer, S. J., J. Fingeroth, J. J. Reilly, S. P. Perrine, and D. V. Faller. 1998. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus-associated lymphoma. Blood Cells Mol. Dis. 24:114-123.
40. Mentzer, S. J., S. P. Perrine, and D. Faller. 2001, Epstein-Barr virus posttransplant lymphoproliferative disease and virus-specific therapy: pharmacological reactivation of viral target genes with arginine butyrate. Transplant Infect. Dis. 3:177-185.
41. Moore, S. M., J. S. Cannon, Y. Tanhehco, F. Hamzeh, and R. Ambinder. 2001. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother. 45:2082-2091.
42. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein disrupts latency in B lymphocytes. J. Virol. 72:7978-7984.
43. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2627. In B. Fields, D. Knipe, and P. Howley (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, Pa.
44. Rooney, C., N. Taylor, J. Countryman, H. Jenson, J. Kolman, and G. Miller. 1988. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA 85:9801-9805.
45. Roychowdhury, S., R. Peng, R. A. Baiocchi, D. Bhatt, S. Vourganti, J. Grecula, N. Gupta, C. F. Eisenbeis, G. J. Nuovo, W. Yang, P. Schmalbrock, A. Ferketich, M. Moeschberger, P. Porcu, R. F. Barth, and M. A. Caligiuri. 2003. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 63:965-971.
46. Speck, S. H., T. Chatila, and E. Flemington. 1997. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5:399-405.
47. Sugawara, Y., M. Makuuchi, and K. Takada. 2000. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand. J. Gastroenterol. 35:981-984.
48. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 33:27-32.
49. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022.
50. van Dam, H., D. Wilhelm, I. Herr, A. Steffen, P. Herrlich, and P. Angel. 1995. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J. 14:1798-1811.
51. Wang, Y. C., J. M. Huang, and E. A. Montalvo. 1997. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227:323-330.
52. Westphal, E. M., W. Blachstock, W.-H. Feng, B. Israel, and S. C. Kenney. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60:5781-5788.
53. Westphal, E. M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1485-1491.
54. Zalani, S., E. A. Holley-Guthrie, D. E. Gutsch, and S. C. Kenney. 1992. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J. Virol. 66:7282-7289.
55. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1995. The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J. Virol. 69:3816-3823.
56. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.
57. Zhao, M., L. New, V. V. Kravchenko, Y. Kato, H. Gram, F. di Padova, E. N. Olson, R. J. Ulevitch, and J. Han. 1999. Regulation of the MEF2 family of transcription factors by p38. Mol. Cell. Biol. 19:21-30.
58. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272:373-375.